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Vitiligo is a depigmenting disorder of the skin that is characterized by the loss of functional melanocytes from
the lesional sites. Although the exact etiology is not understood, autoimmunity is thought to be a crucial
deterministic factor. A recurring theme of several autoimmune disorders is the aberrant presentation of self-
antigens to the immune system, which triggers downstream perturbations. Here we examine the role of alleles
of HLA class I and class II loci to delineate vitiligo manifestation in two distinct populations. Our studies have
identified three specific alleles, HLA-A*33:01, HLA-B*44:03, and HLA-DRB1*07:01, to be significantly increased in
vitiligo patients as compared with controls in both the initial study on North Indians (N¼ 1,404) and the
replication study in Gujarat (N¼ 355) cases, establishing their positive association with vitiligo. Both generalized
and localized vitiligo have the same predisposing major histocompatibility complex alleles, i.e., B*44:03 and
DRB1*07:01, in both the populations studied, beside the differences in the frequencies of other alleles,
suggesting that localized vitiligo too may be an autoimmune disorder. Significant differences in the amino-acid
signatures of the peptide-binding pockets of HLA-A and HLA-B a-chain and HLA-DR b-chain were observed
between vitiligo patients and unaffected controls.
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INTRODUCTION
Vitiligo is a multifactorial, depigmenting disorder of the skin
characterized by loss of functional melanocytes, resulting in
appearance of milky white patches on the skin. It is the most
common pigmentation disorder affecting 0.5–1% of the world
population (Taieb and Picardo, 2007). In India, the incidence
varies from 0.25 to 2.5% (Das et al., 1985; Handa and Kaur,
1999) in most ethnic groups, with 8.8% in populations from
western states of Gujarat and Rajasthan (Shajil et al., 2006).
Vitiligo manifests in broadly two clinical subtypes: general-
ized and localized (Taieb and Picardo, 2007). Generalized
vitiligo includes vitiligo vulgaris, acrofacial vitiligo, and
vitiligo universalis. Localized vitiligo includes segmental
and focal types (Taieb and Picardo, 2007). Precise etiology
of vitiligo is not known; however, several hypotheses have
been proposed, which include autoimmune (Kemp et al.,
2001), neural (Dell’anna and Picardo, 2006), autocytotoxic
(Lerner, 1971), and genetic hypotheses (Bhatia et al., 1992). Of
these, autoimmune hypothesis remains most widely accepted
because of frequent occurrence of other autoimmune diseases
in vitiligo cases, the presence of autoreactive T cells in the
vitiligenous lesions and peripheral circulation, and the
presence of circulating autoantibodies in the sera of the
patients (Schwartz and Janniger, 1997; Kovacs, 1998; Kemp
et al., 2001; Lang et al., 2001; Wankowicz-Kalinska et al.,
2003; van den Boorn et al., 2009; Waterman et al., 2010). The
frequency of vitiligo cases in first-degree relatives is B7%,
suggesting an important role of genetic factors in disease
pathogenesis (Majumder et al., 1993; Alkhateeb et al., 2003).
The major histocompatibility complex (MHC) has been
implicated in recent genome-wide association studies on
vitiligo (Jin et al., 2010; Quan et al., 2010), in which several
single-nucleotide polymorphisms in the MHC region were
significantly associated with the disease. However, the
authors imputed the HLA (MHC of man) class I alleles, based
on the linkage disequilibrium (LD) of HLA alleles with the
specific single-nucleotide polymorphisms, but could not
impute HLA class II alleles because of limitations of HLA
allele imputation in the Chinese Han from Beijing (China)
samples (Quan et al., 2010). MHC spans about 3.6
megabases on chromosome 6p21.3 of man (Horton et al.,
2004), with 224 known gene loci. HLA is the most
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polymorphic system of the human genome, with 1,519 alleles
for HLA-A locus, 2,069 alleles of HLA-B locus, 1,016 alleles
for HLA-C locus, and 966 alleles for HLA-DRB1.
With such a great diversity at each locus, LD of HLA alleles
with diallelic single-nucleotide polymorphisms may be
misleading, as several HLA alleles may be in LD with one
or the alternate single-nucleotide polymorphism. Thus, the
derivation based on these LDs may not be accurate, especially
in the populations from which no previous HLA data are
available. Thus, it is important to study the frequencies of HLA
alleles in patients rather than imputing based on LD.
Many autoimmune diseases such as Type 1 diabetes (Todd
et al., 1987; Rani et al., 2004) and rheumatoid arthritis
(Winchester, 1994) have been shown to be associated with
specific alleles of one or more genes of the MHC. The
association of multiple HLA class I and class II antigens have
been suggested for vitiligo (de Vijlder et al., 2004; Zhang
et al., 2004a, b), although no consensus could be reached,
because of distinct ethnic groups (Zamani et al., 2001; Tastan
et al., 2004; Orozco-Topete et al., 2005), small sample sizes,
and low-resolution typing methods used to identify the HLA
antigens. We report here a very robust study on a sample size
of 1,404 vitiligo cases and 902 unaffected controls from
North India for the alleles at HLA-A, -B, and -C (class I), and
-DRB1 (class II) loci using molecular methods. The replica-
tion study was conducted on 355 cases and 441 controls from
Gujarat (Table 1). We also report differences in the amino-
acid signatures of peptide-binding pockets of the HLA
molecules in vitiligo patients as compared with controls.
RESULTS
HLA class I and II alleles and haplotypes in vitiligo cases as
compared with unaffected controls
Diversity in the number and frequencies of HLA alleles was
observed both in patients and controls. We observed 78, 160,
35, and 106 alleles for HLA-A, -B, -C, and -DRB1 loci,
respectively, in cases, and 68, 111, 44, and 94 alleles for HLA-
A, -B, -C, and -DRB1 loci, respectively, in unaffected controls
from North India, and similar diversity was observed in the
replication study. However, HLA-A*33:01, B*44:03, C*07:01,
DRB1*07:01, and DRB1*12:02 were significantly increased,
and HLA-A*26:01, A*31:01, B*08:01, B*51:01, C*12:03,
DRB1*03:01,DRB1*11:01, andDRB1*15:02were significantly
reduced (Table 2 and Supplementary Table S1 online) in the
vitiligo subjects from North India as compared with controls. In
the replication study, we observed HLA-A*33:01, B*44:03, and
DRB1*07:01 to be significantly increased, and DRB1*03:01
and DRB1*11:01 to be significantly reduced in the cases as
compared with ethnically matched controls (Table 2). These
associations were significant, irrespective of the age at onset or
the gender of the cases (Supplementary Tables S2–S5 online).
To determine which HLA alleles were significantly
associated with vitiligo in the absence of DRB1*07:01, we
deleted all the samples with DRB1*07:01 from both the case
and control groups and then analyzed the data. B*37:01 and
DRB1*10:01 were significantly increased, whereas B*08:01
and DRB1*03:01 (Table 3) were significantly reduced
in vitiligo cases in both initial and replication studies. In
A*33:01-negative cases, B*37:01, B*44:03, DRB1*07:01,
and DRB1*10:01 were significantly increased and
DRB1*03:01 was significantly reduced as compared with
A*33:01-negative controls in both initial and replication
studies (Supplementary Table S6 online). In B*44:03-negative
cases too, we observed a significant increase of B*37:01,
DRB1*07:01, and DRB1*10:01 and a significant decrease of
DRB1*03:01 as compared with B*44:03-negative controls in
both the populations studied (Supplementary Table S7
online). DRB1*07:01 remained significantly increased in
B*37:01-negative patient samples also from North India
(Po5.69 1033, odds ratio (OR)¼3.03, 95% confidence
interval (CI)¼ 2.51–3.66) and Gujarat (Po1.33 1017,
OR¼3.87, 95% CI¼2.78–5.39, data not shown).
HLA-C alleles were studied only in North Indian vitiligo
cases (N¼ 404) and healthy controls (N¼ 438). We did not
see any significant increase in HLA-C group 1 and group 2
alleles (based on Ser77/Asn80 and Asn77/Lys80, respectively) in
vitiligo as compared with controls (Supplementary Table S1
online). In the absence of C*07:01, which was significantly
increased in vitiligo cases, DRB1*07:01 still remained
significantly increased (30% in vitiligo vs. 23.08% in
controls) in cases as compared with controls (Po0.047,
OR¼1.42, 95% CI¼0.99–2.06). However, in DRB1*07:01-
negative samples, C*07:01 does not remain significant
(14.09% in vitiligo vs. 8.81% in controls) in vitiligo cases
when compared with controls (Po0.053, OR¼1.69, 95%
CI¼0.95–3.03), suggesting that association of C*07:01 is
probably because of it being in LD with DRB1*07:01.
Estimation of HLA haplotype frequencies was done using
the expectation maximization algorithm (Excoffier and
Slatkin, 1995; Excoffier et al., 2005) with Arlequin Ver 3.5
Table 1. Description of vitiligo patients and controls used in the study
Unaffected controls Vitiligo patients
Population
Unaffected controls
(males, females,
age mean±SD)
Total vitiligo patients
(males, females, age mean±SD,
age at onset mean±SD)
Generalized vitiligo
(males, females, age mean±SD,
age at onset mean±SD)
Localized vitiligo
(males, females, age mean±SD,
age at onset mean±SD)
North India 902 (538, 364,
36.35±14.75)
1,404 (838, 566, 28.72±14.59,
22.15±14.32)
1,097 (649, 448, 29.44±15.04,
22.34±14.61)
307 (189, 118, 26.16±12.50,
21.46±13.22)
Gujarat
(replication study)
441 (264, 177,
28.04±14.97)
355 (148, 207, 31.18±15.03,
15.70±12.65)
250 (107, 143, 32.06±14.82,
16.14±12.61)
105 (41, 64, 29.12±15.37,
14.66±12.76)
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(http://cmpg.unibe.ch/software/arlequin35/). Haplotype ana-
lysis for three loci showed that haplotypes A*33:01-B*44:03-
DRB1*07:01 and A*24:02-B*44:03-DRB1*07:01 were sig-
nificantly increased, and A*26:01-B*080:01-DRB1*03:01
was significantly reduced in vitiligo patients in both initial
and the replication studies (Table 4). Analysis of two-locus
haplotypes revealed that (Table 5) haplotypes A*33:01-
DRB1*07:01 and B*44:03-DRB1*07:01 were significantly
increased, and A*26:01-DRB1*03:01 was significantly re-
duced in vitiligo cases, in both initial and replication studies.
Four-locus haplotypes were constructed for North Indian
samples and a significant increase of A*33:01-C*07:01-
B*44:03-DRB1*07:01 and A*02:01-C*07:01-B*44:03-DRB1*
07:01, and a significant reduction in haplotype A*26:01-C*
07:02-B*08:01-DRB1*03:01 in vitiligo patients was observed
as compared with controls (Supplementary Table S8 online).
HLA class I and II alleles and haplotypes in different
manifestations of vitiligo: generalized and localized vitiligo as
compared with unaffected controls
To study the association of MHC alleles with different
manifestations of vitiligo, cases were divided into two clinical
types—generalized and localized. A*33:01, B*44:03,
C*07:01, and DRB1*07:01 were significantly increased in
Table 2. HLA-A,HLA-B, andHLA-DRB1 alleles showing significant differences in vitiligo patients as compared with
unaffected controls from North India and Gujarat
Vitiligo Generalized Localized Controls
Vitiligo versus
unaffected controls
Generalized vitiligo
versus controls
Localized vitiligo
versus controls
HLA allele No. (%) No. (%) No. (%) No. (%) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
A*02:01 N India 197 (14.03) 160 (14.59) 37 (12.05) 88 (9.76) 0.002 1.50 (1.14–1.98) 0.001 1.57 (1.18–2.10) 0.25 1.26 (0.82–1.93)
Gujarat 27 (7.62) 17 (6.80) 10 (9.62) 44 (10.78) 0.13 0.68 (0.40–1.15) 0.087 0.60 (0.32–1.11) 0.72 0.88 (0.38–1.86)
A*26:01 N India 83 (5.91) 64 (5.83) 19 (6.19) 90 (9.98) 0.00029 0.56 (0.41–0.78) 0.0005 0.56 (0.39–0.79) 0.045 0.59 (0.34–1.00)
Gujarat 21 (5.93) 15 (6.0) 6 (5.76) 36 (8.82) 0.13 0.65 (0.35–1.17) 0.18 0.66 (0.33–1.27) 0.31 0.63 (0.21–1.57)
A*31:01 N India 43 (3.06) 32 (2.92) 11 (3.58) 58 (6.43) 0.0001 0.45 (0.30–0.70) 0.0002 0.43 (0.27–0.69) 0.063 0.54 (0.25–1.05)
Gujarat 16 (4.51) 13 (5.2) 3 (2.88) 18 (4.41) 0.94 1.02 (0.48–2.16) 0.64 1.18 (0.53–2.61) 0.351 0.72 (0.31–1.65)2
A*33:01 N India 353 (25.14) 276 (25.16) 77 (25.08) 104 (11.53) 1.211015 2.57 (2.02–3.29) 1.091014 2.57 (2.00–3.33) 9.01109 2.56 (1.82–3.61)
Gujarat 69 (19.49) 53 (21.2) 16 (15.38) 51 (12.5) 0.008 1.69 (1.12–2.56) 0.003 1.88 (1.20–2.93) 0.43 1.27 (0.65–2.40)
A*68:01 N India 189 (13.46) 161 (14.68) 28 (9.12) 139 (15.41) 0.19 0.85 (0.66–1.09) 0.64 0.94 (0.73–1.21) 0.0058 0.55 (0.34–0.85)
Gujarat 71 (20.05) 55 (22.0) 16 (15.38) 46 (11.27) 0.0008 1.97 (1.29–3.02) 0.0002 2.21 (1.41–3.49) 0.25 1.43 (0.72–2.71)
B*08:01 N India 68 (4.84) 53 (4.83) 15 (4.89) 112 (12.42) 3.681011 0.35 (0.25–0.49) 8.631010 0.35 (0.25–0.50) 0.0002 0.36 (0.19–0.64)
Gujarat 27 (7.64) 17 (6.85) 10 (9.52) 38 (9.33) 0.40 0.80 (0.46–1.38) 0.26 0.71 (0.37–1.33) 0.95 1.02 (0.43–2.18)
B*37:01 N India 95 (6.77) 76 (6.93) 19 (6.19) 41 (4.55) 0.027 1.54 (1.03–2.27) 0.023 1.56 (1.04–2.37) 0.25 1.38 (0.76–2.49)
Gujarat 43 (12.18) 29 (11.69) 14 (13.33) 26 (6.38) 0.0056 2.03 (1.18–3.52) 0.018 1.94 (1.07–3.52) 0.018 2.25 (1.04–4.68)
B*44:03 N India 419 (29.84) 347 (31.63) 72 (23.45) 97 (10.75) 7.051027 3.53 (2.76–4.53) 5.411029 3.83 (2.98–4.96) 2.98108 2.54 (1.78–3.61)
Gujarat 88 (24.92) 66 (26.61) 22 (20.95) 39 (9.58) 1.54 108 3.13 (2.04–4.84) 8.29 109 3.42 (2.17–5.42) 0.001 2.50 (1.33–4.58)
B*51:01 N India 133 (9.47) 114 (10.39) 19 (6.19) 167 (18.51) 3.001010 0.46 (0.35–0.59) 2.00 107 0.51 (0.39–0.66) 2.34107 0.29 (0.17–0.48)
Gujarat 46 (13.03) 33 (13.30) 13 (12.38) 45 (11.05) 0.40 1.20 (0.76–1.91) 0.38 1.23 (0.74–2.04) 0.70 1.13 (0.54–2.25)
DRB1*03:01 N India 92 (6.55) 67 (6.11) 25 (8.14) 174 (19.29) 9.231021 0.29 (0.22–0.38) 2.101019 0.27 (0.19–0.37) 5.37106 0.37 (0.23–0.58)
Gujarat 22 (6.19) 14 (5.6) 8 (7.61) 61 (13.83) 0.00045 0.41 (0.23–0.70) 0.0008 0.37 (0.18–0.68) 0.08 0.51 (0.20–1.12)
DRB1*07:01 N India 724 (51.57) 601 (54.79) 123 (40.07) 248 (27.49) 3.161030 2.80 (2.33–3.37) 1.101034 3.19 (2.63–3.87) 0.000037 1.76 (1.33–2.33)
Gujarat 184 (51.83) 133 (53.2) 51 (48.57) 111 (25.17) 9.811015 3.19 (2.34–4.36) 1.281013 3.37 (2.39–4.75) 2.38106 2.80 (1.76–4.45)
DRB1*11:01 N India 87 (6.20) 64 (5.83) 23 (7.49) 93 (10.31) 0.0003 0.57 (0.41–0.78) 0.0002 0.53 (0.38–0.76) 0.14 0.70 (0.42–1.15)
Gujarat 19 (5.35) 16 (6.4) 3 (2.85) 57 (12.92) 0.0003 0.38 (0.21–0.67) 0.0073 0.46 (0.24–0.84) 0.00101 0.22 (0.10–0.49)2
DRB1*12:02 N India 67 (4.77) 53 (4.83) 14 (4.56) 14 (1.55) 0.00004 3.17 (1.75–6.16) 0.00005 3.22 (1.74–6.32) 0.0025 3.03 (1.32–6.93)
Gujarat 14 (3.94) 11 (4.4) 4 (3.80) 23 (5.21) 0.51 0.80 (0.38–1.63) 0.63 0.83 (0.36–1.82) 0.381 0.78 (0.38–1.63)2
DRB1*15:02 N India 165 (11.75) 117 (10.67) 48 (15.64) 152 (16.85) 0.0005 0.65 (0.51–0.84) 0.00005 0.59 (0.45–0.77) 0.62 0.91 (0.63–1.31)
Gujarat 54 (15.21) 37 (14.8) 17 (16.19) 82 (18.59) 0.20 0.78 (0.52–1.16) 0.20 0.76 (0.48–1.18) 0.56 0.84 (0.44–1.52)
Abbreviations: CI, confidence interval; N, North; OR, odds ratio.
1P-value calculated using Fisher’s exact test.
2OR was calculated by using Woolf’s method with Haldane’s modification.
Vitiligo patient samples from North India (N=1,404; generalized (n=1,097), localized (n=307)) were compared with unaffected controls (N=902, North
Indian origin) for HLA-A, HLA-B, and HLA-DRB1 loci. Overall, 354 vitiligo patients, 250 generalized and 104 localized, were compared with 408
Gujarati controls for HLA-A locus. Overall, 353 vitiligo patients, 248 generalized and 105 localized, were compared with 407 Gujarati controls for HLA-B
locus, and 355 vitiligo patients, 250 generalized and 105 localized, were compared with 441 Gujarati controls for HLA-DRB1 locus.
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Table 3. HLA-A, HLA-B, and HLA-DRB1 alleles showing significant differences in all vitiligo and generalized and
localized vitiligo as compared with healthy controls in DRB1*07:01-negative samples in North Indian and
Gujarat populations
Vitiligo
Generalized
vitiligo
Localized
vitiligo Controls
Vitiligo versus
controls
Generalized vitiligo
versus controls
Localized vitiligo
versus controls
HLA allele No. (%) No. (%) No. (%) No. (%) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
HLA-A
A*02:01 N India 92 (13.53) 70 (14.11) 22 (11.96) 68 (10.40) 0.078 1.34 (0.95–1.91) 0.055 1.41 (0.97–2.05) 0.54 1.17 (0.66–1.98)
Gujarat 13 (7.65) 8 (6.84) 5 (9.43) 42 (13.38) 0.058 0.53 (0.25–1.05) 0.059 0.47 (0.18–1.06) 0.291 0.72 (0.37–1.41)2
A*24:02 N India 146 (21.47) 105 (21.17) 41 (22.28) 143 (21.87) 0.86 0.97 (0.74–1.27) 0.77 0.95 (0.71–1.28) 0.90 1.02 (0.67–1.53)
Gujarat 32 (18.82) 23 (19.66) 9 (16.98) 88 (28.03) 0.025 0.59 (0.36–0.95) 0.077 0.62 (0.35–1.07) 0.09 0.52 (0.21–1.15)
A*26:01 N India 41 (6.03) 32 (6.45) 9 (4.89) 69 (10.55) 0.0027 0.54 (0.35–0.82) 0.015 0.58 (0.36–0.92) 0.019 0.43 (0.18–0.90)
Gujarat 11 (6.47) 8 (6.84) 3 (5.66) 37 (11.78) 0.061 0.51 (0.23–1.07) 0.13 0.54 (0.21–1.24) 0.131 0.51 (0.22–1.14)2
A*31:01 N India 24 (3.53) 17 (3.43) 7 (3.80) 50 (7.65) 0.001 0.44 (0.25–0.74) 0.0025 0.42 (0.22–0.76) 0.06 0.47 (0.18–1.08)
Gujarat 9 (5.29) 7 (5.98) 2 (3.77) 16 (5.10) 0.92 1.04 (0.39–2.56) 0.71 1.18 (0.40–3.14) 0.501 0.87 (0.33–2.29)2
A*33:01 N India 94 (13.82) 59 (11.90) 35 (19.02) 71 (10.86) 0.09 1.31 (0.93–1.85) 0.58 1.10 (0.75–1.62) 0.003 1.92 (1.19–3.05)
Gujarat 20 (11.76) 15 (12.82) 5 (9.43) 34 (10.83) 0.75 1.09 (0.57–2.04) 0.56 1.21 (0.58–2.39) 0.491 0.92 (0.47–1.80)2
A*68:01 N India 107 (15.74) 87 (17.54) 20 (10.87) 100 (15.29) 0.82 1.03 (0.76–1.40) 0.30 1.17 (0.84–1.63) 0.13 0.67 (0.38–1.14)
Gujarat 44 (25.88) 32 (27.35) 12 (22.64) 38 (12.10) 0.0001 2.53 (1.52–4.23) 0.0001 2.73 (1.54–4.79) 0.038 2.12 (0.93–4.57)
HLA-B
B*08:01 N India 37 (5.44) 30 (6.05) 7 (3.80) 96 (14.68) 1.80108 0.33 (0.21–0.50) 3.47106 0.37 (023–0.58) 0.00007 0.22 (0.08–0.50)
Gujarat 8 (4.71) 4 (3.45) 4 (3.45) 32 (10.32) 0.033 0.42 (0.16–0.98) 0.0141 0.34 (0.16–0.70)2 0.351 0.76 (0.37–1.58)2
B*13:01 N India 40 (5.88) 30 (6.05) 10 (5.43) 15 (2.29) 0.00098 2.66 (1.42–5.23) 0.001 2.74 (1.41–5.54) 0.02 2.44 (0.96–5.92)
Gujarat 5 (2.94) 3 (2.59) 2 (1.72) 2 (0.65) 0.0571 4.10 (1.41–11.90)2 0.121 3.80 (1.19–12.11)2 0.101 5.87 (1.67–20.64)2
B*15:02 N India 39 (5.74) 29 (5.85) 10 (5.43) 16 (2.45) 0.002 2.42 (1.30–4.9) 0.003 2.47 (1.28–4.93) 0.038 2.29 (0.91–5.47)
Gujarat 16 (9.41) 13 (11.21) 3 (2.59) 26 (8.39) 0.70 1.13 (0.55–2.27) 0.34 1.39 (0.63–2.94) 0.341 0.72 (0.32–1.65)2
B*37:01 N India 70 (10.29) 53 (10.69) 17 (9.24) 29 (4.43) 0.00004 2.47 (1.55–4.01) 0.00004 2.57 (1.57–4.27) 0.01 2.19 (1.10–4.24)
Gujarat 29 (17.06) 19 (16.38) 10 (8.62) 23 (7.42) 0.001 2.56 (1.37–4.82) 0.0057 2.44 (1.19–4.90) 0.008 2.83 (1.12–6.68)
B*44:03 N India 39 (5.74) 24 (4.84) 15 (8.15) 18 (2.75) 0.007 2.14 (1.18–4.03) 0.06 1.79 (0.92–3.55) 0.00087 3.13 (1.43–6.73)
Gujarat 4 (2.35) 3 (2.59) 1 (0.8) 14 (4.52) 0.171 0.55 (0.26–1.18)2 0.271 0.63 (0.27–1.45)2 0.311 0.57 (0.17–1.91)2
B*51:01 N India 93 (13.68) 79 (15.93) 14 (7.61) 138 (21.10) 0.0003 0.59 (0.43–0.79) 0.026 0.70 (0.51–0.97) 0.000027 0.30 (0.16–0.55)
Gujarat 23 (13.53) 16 (13.79) 7 (6.03) 42 (13.55) 0.99 0.99 (0.55–1.77) 0.94 1.02 (0.51–1.95) 0.90 0.95 (0.33–2.30)
B*57:01 N India 24 (3.53) 17 (3.43) 7 (3.80) 25 (3.82) 0.77 0.92 (0.49–1.69) 0.72 0.89 (0.44–1.74) 0.99 0.99 (0.35–2.41)
Gujarat 8 (4.71) 3 (2.59) 5 (4.31) 22 (7.10) 0.30 0.64 (0.24–1.55) 0.0551 0.39 (0.17–0.89)2 0.371 1.42 (0.71–2.84)2
B*58:01 N India 39 (5.74) 24 (4.84) 15 (8.15) 59 (9.02) 0.02 0.61 (0.39–0.95) 0.006 0.51 (0.30–0.85) 0.71 0.89 (0.45–1.64)
Gujarat 7 (4.12) 3 (2.59) 4 (3.45) 16 (5.16) 0.60 0.78 (0.26–2.08) 0.191 0.55 (0.24–1.26)2 0.341 1.59 (0.74–3.42)2
HLA-DRB1
DRB1*01:01 N India 35 (5.15) 25 (5.04) 10 (5.43) 35 (5.35) 0.86 0.95 (0.57–1.60) 0.81 0.93 (0.53–1.63) 0.96 1.01 (0.44–2.15)
Gujarat 4 (2.34) 2 (1.71) 2 (3.70) 25 (7.58) 0.011 0.32 (0.15–0.66)2 0.011 0.25 (0.10–0.65)2 0.231 0.57 (0.22–1.46)2
DRB1*03:01 N India 65 (9.56) 49 (9.88) 16 (8.70) 155 (23.70) 3.461012 0.34 (0.24–0.46) 1.22109 0.35 (0.24–0.50) 8.13106 0.30 (0.16–0.53)
Gujarat 12 (7.02) 7 (5.98) 5 (9.26) 60 (18.18) 0.0007 0.33 (0.16–0.66) 0.0015 0.28 (0.10–0.65) 0.0711 0.49 (0.26–0.95)2
DRB1*04:03 N India 65 (9.56) 46 (9.27) 19 (10.33) 47 (7.19) 0.11 1.36 (0.90–2.06) 0.19 1.32 (0.84–2.06)2 0.16 1.48 (0.80–2.66)
Gujarat 2 (1.17) 0 (0.00) 2 (3.70) 24 (7.27) 0.00161 0.18 (0.07–0.46)2 0.00051 0.05 (0.007–0.38)2 0.261 0.59 (0.23–1.52)2
DRB1*10:01 N India 105 (15.44) 81 (16.33) 24 (13.04) 64 (9.79) 0.0019 1.68 (1.19–2.38) 0.0009 1.79 (1.24–2.59) 0.20 1.38 (0.80–2.32)
Gujarat 40 (23.39) 26 (22.22) 14 (25.93) 39 (11.82) 0.0007 2.27 (1.35–3.81) 0.006 2.13 (1.17–3.81) 0.005 2.61 (1.19–5.43)
DRB1*11:01 N India 73 (10.74) 56 (11.29) 17 (9.24) 77 (11.77) 0.55 0.90 (0.63–1.28) 0.79 0.95 (0.64–1.39) 0.33 0.76 (0.41–1.34)
Gujarat 20 (11.70) 17 (14.53) 3 (5.56) 41 (12.42) 0.81 0.93 (0.49–1.69) 0.56 1.19 (0.60–2.27) 0.101 0.47 (0.21–1.05)2
DRB1*12:02 N India 52 (7.65) 41 (8.27) 11 (5.98) 12 (1.83) 6.84107 4.42 (2.30–9.19) 2.58107 4.82 (2.44–10.17) 0.002 3.40 (1.33–8.56)
Table 3 continued on following page
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the initial study in both generalized and localized vitiligo.
However, only B*44:03 and DRB1*07:01 were associated in
the replication study with both the generalized and localized
types of vitiligo (Table 2 and Supplementary Table S1 online).
Alleles associated with different manifestations of vitiligo
were HLA-A*02:01, B*37:01, B*57:01, DRB1*04:03, and
DRB1*10:01, which were significantly increased, and
A*31:01, B*58:01, C*04:01, DRB1*01:01, DRB1*11:01,
and DRB1*15:02 were significantly reduced in generalized
vitiligo cases and not in localized vitiligo cases from North
India. HLA-A*30:01, A*33:01, and A*68:01 were signifi-
cantly increased, and B*58:01 and DRB1*01:01 were
significantly reduced in generalized vitiligo cases and not in
localized vitiligo cases from Gujarat as compared with
unaffected controls.
In the absence of DRB1*07:01, B*37:01 was significantly
increased in both North Indian and Gujarati patients,
irrespective of the type of vitiligo. In addition, A*68:01 and
DRB1*10:01 were significantly increased in patients from
Gujarat and B*13:01, B*15:02, DRB1*12:02, and
DRB1*14:04 were significantly increased in North Indian
patients, irrespective of the type of vitiligo. A*33:01 and
B*44:03 were increased in localized cases and DRB1*10:01
was increased in generalized cases from North India
(Table 3).
Haplotype A*33:01-B*44:03-DRB1*07:01 (Table 4) was
significantly increased in both generalized and localized
cases in the initial study and only in generalized cases in the
replication study. A*24:02-B*44:03-DRB1*07:01 was signifi-
cantly increased in generalized cases from North India,
whereas both generalized and localized cases from Gujarat
showed a significant increase in the frequency of this
haplotype when compared with unaffected controls. Haplo-
type A*02:01-B*44:03-DRB1*07:01 was significantly in-
creased in both generalized and localized vitiligo cases
from North India.
Two-locus haplotype analysis showed that B*44:03-
DRB1*07:01 was significantly increased in both generalized
and localized cases in both initial and replication studies
(Table 5). A*33:01-DRB1*07:01 and A*02:01-DRB1*07:01
were significantly increased in both generalized and loca-
lized vitiligo cases in the initial study; however, only
haplotype A*33:01-DRB1*07:01 was significantly increased
in generalized vitiligo cases from Gujarat. Haplotype
A*26:01-DRB1*03:01 was significantly reduced in both
generalized and localized cases from North India and
Gujarat, although P-value did not reach statistical signifi-
cance for localized cases from Gujarat because of smaller
sample size. B*08:01-DRB1*03:01 was significantly reduced
in both generalized and localized vitiligo cases from North
India and Gujarat.
Specific amino-acid signatures of HLA peptide-binding
pockets predispose to vitiligo
Amino-acid signatures of the peptide-binding pockets of
HLA-A, -B, and -DRB1 were compared in vitiligo cases with
unaffected controls (Figure 1 and Supplementary Tables S9
and S10 online). For HLA-A and -B, five key residues
constituting the B pocket (positions 9, 45, 63, 66, and 67)
and four key residues constituting the F pocket (positions 77,
80, 81, and 116) of the a1 and a2 domains of the a-chain
were investigated (Sidney et al., 2008). For DRB1, 11 residues
representing integral parts of peptide-binding pockets of DR
b-chain were analyzed at positions 26, 28, 30, 37, 47, 67, 70,
71, 74, 77, and 86 (Menconi et al., 2010). The protein
sequences were downloaded from the HLA database (http://
www.ebi.ac.uk/imgt/hla/align.html), and the amino acids
present at the aforesaid positions were compared in patients
and controls. Approximately 8–10% of the samples were
homozygous for one or more loci in patients and controls.
Thus, to avoid overrepresentation of certain amino acids at
particular positions because of homozygosity, we considered
phenotype frequencies of the alleles; i.e., the homozygous
samples were counted as having only one allele. The results
show that that Glu28b, Leu30b/Arg30b Phe37b, Tyr47b, Ile67b,
Asp70b, Arg71b, Gln74b, Thr77b, and Gly86b make the
molecular signature of the peptide-binding pockets of DRB1
for predisposition to develop vitiligo in both the initial and
replication studies (Figure 1). Asp28b, Tyr30b/Cys30b, Ser37b,
Phe47b, Leu67b, Gln70b, Lys71b, Ala/Arg74b, Asn77b, and Val86b
Table 3. Continued
Vitiligo
Generalized
vitiligo
Localized
vitiligo Controls
Vitiligo versus
controls
Generalized vitiligo
versus controls
Localized vitiligo
versus controls
HLA allele No. (%) No. (%) No. (%) No. (%) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
Gujarat 12 (7.02) 10 (8.55) 2 (3.70) 22 (6.67) 0.88 1.05 (0.46–2.29) 0.49 1.30 (0.53–2.98) 0.311 0.65 (0.25–1.68)2
DRB1*14:04 N India 92 (13.53) 62 (12.50) 30 (16.30) 56 (8.56) 0.0039 1.67 (1.16–2.41) 0.029 1.52 (1.02–2.27) 0.002 2.08 (1.24–3.42)
Gujarat 22 (12.87) 16 (13.68) 6 (11.11) 39 (11.82) 0.73 1.10 (0.59–1.98) 0.13 1.51 (0.83–2.68) 0.88 0.93 (0.30–2.38)
Abbreviations: CI, confidence interval; N, North; OR, odds ratio.
1P-value was calculated by using Fisher’s exact test.
2OR was calculated by using Woolf’s method with Haldane’s modification.
All patient and control samples with DRB1*07:01 allele were removed to study the contribution of alleles independent of DRB1*07:01 in susceptibility
to vitiligo. All vitiligo (N=680), generalized (N=496), and localized (N=184) vitiligo samples from North India were compared with healthy controls
(N=654) for HLA-A, HLA-B, and HLA-DRB1 loci. From Gujarat, all vitiligo (N=170), generalized (N=117), and localized (N=53) vitiligo samples
were compared with 314 unaffected controls for HLA-A locus. Overall, 170 vitiligo samples, 116 generalized and 54 localized, were compared with
314 samples from unaffected controls for HLA-B locus, and 171 vitiligo samples, 117 generalized and 54 localized, were compared with 330 unaffected
controls for HLA-DRB1 locus.
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make the molecular signature of DRB1 for the protection
from vitiligo in both North India and Gujarat. The molecular
signature for HLA-A alleles for predisposition to develop the
disease is actually specific for HLA-A allele A*33:01, which is
in LD with DRB1*07:01. For HLA-B locus, Lys45a, Glu63a,
Ser67a, Asn77a, Thr80a, Ala81a, and Ser99a makes the
molecular signature for predisposition to develop vitiligo,
and Thr45a, Asn63a, Phe67a, Ser77a, Asn80a, Leu81a, and Tyr99a
makes the molecular signature for protection from vitiligo in
both the initial and replication studes. In addition, significant
increase of Met45a, Cys67a, Asp77a, and Asp116a in North
Indian samples suggests the involvement of alleles other than
Table 4. HLA-A-B-DRB1 (three-locus) haplotypes significantly different in vitiligo cases as compared with controls
from North India and Gujarat
North India vitiligo versus North India controls Gujarat vitiligo versus Gujarat controls
HLA haplotype Sample type No. (%) P-value OR (95% CI) No. (%) P-value OR (95% CI)
A*33:01-B*44:03-DRB1*07:01 Controls 27 (2.99) 14 (3.57)
All cases 226 (16.09) 8.75 1023 6.21 (4.01–9.72) 42 (11.93) 0.000016 3.65 (1.91–7.37)
Generalized 189 (17.22) 1.94 1024 6.74 (4.43–10.60) 34 (13.70) 2.09 106 4.28 (2.18–8.83)
Localized 37 (12.05) 9.18 1010 4.44 (2.57–7.72) 8 (7.69) 0.07 2.25 (0.79–5.93)
A*02:01-B*44:03-DRB1*07:01 Controls 0 (0.00) 0 (0.00)
All cases 33 (2.35) 6.66108 1 44.08 (6.11–317.86)2 1 (0.28) 0.471 3.34 (0.34–32.27)2
Generalized 29 (2.64) 2.33108 1 49.83 (6.83–360.03)2 0 (0.00)
Localized 4 (1.30) 0.0041 26.76 (3.38–211.67)2 1 (0.96) 0.201 11.37 (1.17–109.93)2
A*24:02-B*44:03-DRB1*07:01 Controls 4 (0.44) 2 (0.51)
All cases 26 (1.85) 0.00191 3.83 (1.88–7.80)2 12 (3.40) 0.00341 5.73 (2.18–15.06)2
Generalized 23 (2.09) 0.00091 4.37 (2.13–8.93)2 7 (2.82) 0.0201 4.85 (1.75–13.43)2
Localized 3 (0.97) 0.251 2.29 (0.85–6.18)2 5 (4.80) 0.0051 8.63 (2.96–25.13)2
A*26:01-B*08:01-DRB1*03:01 Controls 37 (4.10) 17 (4.33)
All cases 20 (1.42) 0.00005 0.33 (0.18–0.60) 2 (0.56) 0.00071 0.15 (0.05–0.39)2
Generalized 16 (1.45) 0.00025 0.34 (0.18–0.64) 1 (0.40) 0.00161 0.13 (0.04–0.42)2
Localized 4 (1.30) 0.0101 0.34 (0.17–0.68)2 1 (0.96) 0.081 0.31 (0.09–1.02)2
A*01:01-B*57:01-DRB1*07:01 Controls 30 (3.32) 27 (6.88)
All cases 81 (5.76) 0.0075 1.77 (1.42–2.82) 27 (7.67) 0.68 1.12 (0.61–2.03)
Generalized 65 (5.92) 0.0065 1.83 (1.15–2.95) 22 (8.87) 0.35 1.31 (0.70–2.46)
Localized 16 (5.21) 0.13 1.59 (0.80–3.08) 5 (4.80) 0.301 0.73 (0.37–1.43)2
A*11:01-B*44:03-DRB1*07:01 Controls 16 (1.77) 1 (0.25)
All cases 43 (3.06) 0.055 1.74 (0.95–3.34) 9 (2.55) 0.0061 7.21 (2.12–24.49)2
Generalized 36 (3.28) 0.035 1.87 (1.00–3.65) 7 (2.82) 0.0061 8.1 (2.33–28.14)2
Localized 7 (2.28) 0.57 1.29 (0.44–3.36) 2 (1.92) 0.111 6.36 (1.50–26.85)2
A*11:01-B*57:01-DRB1*07:01 Controls 8 (0.99) 15 (3.82)
All cases 14 (0.99) 0.79 1.12 (0.43–3.10) 5 (1.42) 0.0341 0.38 (0.19–0.77)2
Generalized 12 (1.09) 0.64 1.23 (0.46–3.50) 3 (1.20) 0.041 0.34 (0.15–0.79)2
Localized 2 (0.65) 0.511 1.69 (0.54–4.91)2 2 (1.92) 0.271 0.59 (0.22–1.54)2
Abbreviations: CI, confidence interval; OR, odds ratio.
1P-value was calculated by using Fisher’s exact test.
2OR was calculated by using Woolf’s method with Haldane’s modification.
Three-locus haplotypes were constructed using Arlequin ver 3.5 for 1,404 vitiligo patients referred to as all cases in the table (1,097 generalized and
307 localized vitiligo cases) from North India and 352 vitiligo patients from Gujarat (248 generalized and 104 localized vitiligo cases) and compared with
902 and 392 unaffected controls from North India and Gujarat, respectively.
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the predisposing alleles, which may be in low frequencies
(Figure 1, Supplementary Table S10 online).
Subtle differences were observed in the molecular
signatures of the peptide-binding pockets of DR b-chain in
localized and generalized vitiligo. Interestingly, localized
vitiligo patients show similarities in the amino-acid signatures
with generalized vitiligo at positions Glu28b, Leu30b, Phe37b,
Tyr47b, and Gln74b in both the initial and replication studies.
However, they show similarities with unaffected controls
at positions Arg30b/Cys30b, Ser37b, Ile67b/Leu67b Asp70b, and
Table 5. HLA-A-DRB1 and HLA-B-DRB1 (two-locus) haplotypes showing significant differences in vitiligo patients
as compared with controls from North India and Gujarat
North India vitiligo versus North India controls Gujarat vitiligo versus Gujarat controls
HLA haplotype Sample type No. (%) P-value OR (95% CI) No. (%) P-value OR (95% CI)
A*33:01-DRB1*07:01 Controls 29 (7.39) 15 (3.82)
All cases 251 (17.87) 6.971026 6.55 (4.39–10.08) 44 (12.50) 0.00001 3.59 (1.91–7.07)
Generalized 212 (19.32) 3.501028 7.21 (4.81–11.14) 36 (14.51) 1.44106 4.26 (2.21–8.57)
Localized 39 (12.70) 4.581010 4.38 (2.58–7.48) 8 (7.69) 0.09 2.09 (0.74–5.43)
A*02:01-DRB1*07:01 Controls 7 (1.10) 0 (0.00)
All cases 66 (4.70) 1.49 107 6.30 (2.87–16.35) 3 (0.85) 0.101 7.86 (0.96–64.05)2
Generalized 56 (5.10) 3.53 108 6.87 (3.10–17.96) 0 (0.00)
Localized 10 (3.25) 0.001 4.30 (1.46–13.43) 3 (2.88) 0.0091 27.06 (3.31–221.26)2
B*44:03-DRB1*07:01 Controls 82 (9.09) 19 (4.84)
All cases 402 (28.63) 2.431029 4.01 (3.09–5.23) 86 (24.43) 1.84 1014 6.34 (3.71–11.30)
Generalized 343 (31.26) 1.741033 4.54 (3.48–5.97) 63 (25.40) 3.45 1014 6.68 (3.80–12.15)
Localized 59 (19.21) 1.79 106 2.37 (1.62–3.47) 23 (22.11) 1.87108 5.57 (2.74–11.33)
B*57:01-DRB1*07:01 Controls 47 (5.21) 45 (4.98)
All cases 128 (9.11) 0.0005 1.82 (1.28–2.63) 44 (12.50) 0.66 1.10 (0.69–1.75)
Generalized 103 (9.38) 0.0004 1.88 (1.30–2.75) 35 (14.11) 0.32 1.26 (0.76–2.08)
Localized 25 (8.14) 0.60 1.61 (0.93–2.73) 9 (8.65) 0.41 0.73 (0.30–1.58)
A*24:02-DRB1*12:02 Controls 3 (0.33) 13 (3.31)
All cases 12 (0.85) 0.101 2.30 (0.99–5.34)2 3 (0.85) 0.011 0.28 (0.12–0.65)2
Generalized 8 (0.72) 0.181 2.00 (0.82–4.84)2 3 (1.20) 0.0761 0.40 (0.17–0.92)2
Localized 4 (1.30) 0.071 3.81 (1.41–10.27)2 0 (0.00) 0.0451 0.13 (0.02–0.99)2
A*26:01-DRB1*03:01 Controls 37 (4.10) 17 (4.33)
All cases 20 (1.42) 0.00005 0.33 (0.18–0.60) 2 (0.56) 0.00071 0.15 (0.05–0.39)2
Generalized 16 (1.45) 0.00025 0.34 (0.18–0.64) 1 (0.40) 0.00161 0.13 (0.04–0.42)2
Localized 4 (1.30) 0.011 0.34 (0.17–0.69)2 1 (0.96) 0.071 0.31 (0.09–1.02)2
B*08:01-DRB1*03:01 Controls 71 (7.87) 27 (6.88)
All cases 24 (1.70) 3.701013 0.20 (0.12–0.33) 4 (1.61) 0.000041 0.17 (0.08–0.34)2
Generalized 18 (1.64) 1.801011 0.19 (0.11–0.33) 3 (1.20) 0.00041 0.18 (0.08–0.42)2
Localized 6 (1.95) 0.0002 0.23 (0.08–0.54) 1 (0.96) 0.011 0.19 (0.06–0.62)2
Abbreviations: CI, confidence interval; OR, odds ratio.
1P-value was calculated by using Fisher’s exact test.
2OR was calculated by using Woolf’s method with Haldane’s modification.
Two-locus haplotypes (HLA-A-HLA-DRB1 and HLA-B-HLA-DRB1) were deduced from three-locus haplotypes (Arlequin ver 3.5) for patients and controls as
described in Table 4.
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Ala74b in North Indians, and Cys30b, Ser37b, Asp70b, Arg71b/
Lys Ser71b, Ala74b/Arg74b, and Thr77b/Asn77b in Gujaratis
(data not shown).
DISCUSSION
Our results show that A*33:01, B*44:03, and DRB1*07:01
were significantly increased in both initial and replication
studies, suggesting that these alleles are the markers for
vitiligo in both North India and Gujarat. Association of
DRB1*07:01 with vitiligo seems to be primary, because in the
absence of A*33:01, B*44:03, or B*37:01, DRB1*07:01 still
remains highly significant in both the populations studied,
whereas the converse was not true. The basic predisposing
alleles in both localized and generalized vitiligo are the
same; however, similarities with the controls in terms of
allele frequencies of some alleles and amino-acid signature of
the DR b-chain seem to be protective from generalized
distribution of the lesions in localized vitiligo (Supplementary
Table S11 online).
Haplotype analysis showed the presence of 177 and 68
DRB1*07:01 haplotypes in North Indian and Gujarati cases,
respectively, suggesting that enough recombinational events
have taken place during the course of evolution, giving rise
to such a diversity of haplotypes; however, some of the
predisposing and protective haplotypes are still conserved.
The haplotype A*33:01-B*44:03-DRB1*07:01 was signifi-
cantly increased in generalized and localized vitiligo cases
from North India and only generalized cases from Gujarat.
Although the localized cases from Gujarat showed an OR of
2.25 for this haplotype, the P-value was not significant,
probably because of smaller sample size for the localized
cases from Gujarat.
Very few studies have been conducted on association of
HLA alleles with vitiligo using low-resolution molecular
methods and still fewer using high-resolution typing methods.
A study on 41 Turkish vitiligo cases showed DRB1*03,
DRB1*04, and DRB1*07 to be increased in the vitiligo cases
(Tastan et al., 2004). However, we observed DRB1*07:01 to
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Figure 1. Amino-acid signatures for the peptide-binding pockets of HLA molecules. (a) For DR b1-chain in vitiligo patients from North India and Gujarat.
Amino acids shown in red are significantly increased in vitiligo patients; amino acids shown in green are significantly reduced in vitiligo patients as compared
with controls. More than one amino acid at certain positions being red or green suggests the involvement of multiples alleles. (b) Ribbon diagram for peptide-
binding clefts for predisposing and (c) protective DRB1 alleles (using PyMOL software, PyMOL Molecular Graphics System, Schro¨dinger, San Carlos, CA).
(d) Amino-acid signature for HLA-A locus. (e) Amino-acid signature for HLA-B locus in vitiligo. Significantly increased Po0.009 to 1029; Significantly
increased Po0.05–0.01; Significantly reduced Po0.009 to 1028; Significantly reduced Po0.05–0.01; Nonsignificant.
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be positively associated and DRB1*03:01 to be negatively
associated with vitiligo in both initial and replication studies.
Presence of DRB1*07:01 has been reported in patients from
Slovakia (Buc et al., 1998) and China (Ren et al., 2009),
whereas HLA class I alleles have not been reported in these
studies. A meta-analysis of 11 case–control studies (N¼777)
showed that class I allele HLA-A2 is associated with vitiligo
(Liu et al., 2007). HLA-A2 is a cluster of 266 alleles, one of
which, HLA-A*02:01, was significantly increased in general-
ized vitiligo cases (Po0.001, OR¼1.57) from North India,
although only 14.59% of the generalized vitiligo patients
and 9.76% of unaffected controls had this allele (Table 2).
The haplotype A*02:01-B*44:03-DRB1*07:01 was signifi-
cantly increased in both generalized (2.64%) and localized
cases (1.3%) from North India as compared with controls
who lacked this haplotype altogether. However, our data
suggest that the primary association of HLA with vitiligo in
North India and Gujarat is not with A*02:01, but with
A*33:01, B*44:03, and DRB1*07:01.
Analysis of two-locus haplotypes for HLA-A-DRB1 and
HLA-B-DRB1 suggests that the haplotype B*44:03-
DRB1*07:01 is the marker for both generalized and localized
vitiligo in both the populations studied. DRB1*07:01 was
also in LD with A*02:01, A*33:01, and B*57:01. These
data suggest that the autoreactive CD4þ T-helper cells are
restricted by HLA-DRB1*07:01 and the autoreactive CD8þ
cytotoxic T cells may be restricted by HLA-A*33:01,
A*02:01, B*44:03, and B*57:01 in the Indian populations
studied.
Association of MHC alleles with a disease gains impor-
tance because of the antigen-presenting function of the MHC.
The peptides presented by the MHC molecules have allele-
specific motifs (Falk et al., 1991). The affinity of the peptide to
a particular MHC molecule is determined by the amino-acid
residues present in peptide-binding pockets of the peptide-
binding groove. Shared amino acids in the peptide-binding
pockets have been demonstrated in autoimmune diseases
such as Type 1 diabetes (Todd et al., 1987), rheumatoid
arthritis (Winchester, 1994), and thyroiditis (Menconi et al.,
2010). Investigation of amino-acid signatures for the peptide-
binding pockets of HLA-A and HLA-B a-chain and HLA-DR
b-chain revealed specific molecular signatures for predis-
position and protection from the disease. These results
suggest affinity of autoantigenic peptides for predisposing
MHC class II and class I molecules that may be involved in
orchestrating (through CD4þ T cells) and implementing the
autoimmune responses (through CD8þ T cells) in vitiligo,
respectively.
Generalized vitiligo is considered to be an autoimmune
disease, whereas localized vitiligo has not been considered
an autoimmune disease. We observed B*44:03 and
DRB1*07:01 to be predisposing in both generalized and
localized vitiligo patients in both the populations studied,
beside some differences in the frequencies of some other
alleles. To our knowledge, this is previously unreported.
Association of MHC alleles with localized vitiligo clearly
shows that there is a need to relook at the etiopathogenesis of
localized vitiligo. Although it may be an autoimmune
disorder, similarities with unaffected controls in terms of
HLA alleles and amino-acid signatures of the peptide-binding
pockets of DR b-chain may be contributing to the localized
distribution of the lesions.
MATERIALS AND METHODS
Patient group
DNAs were extracted from 1,404 North Indian patients with vitiligo
enrolled at Dr Ram Manohar Lohia Hospital and All India Institute of
Medical Sciences, New Delhi, after obtaining informed consent.
These subjects belonged to North Indian states of Uttar Pradesh,
Himachal Pradesh, Bihar, Haryana, Punjab, and Delhi. All cases and
control samples were collected after Institutional Human Ethics
Committee’s clearance from all the institutes/hospitals involved,
following the Declaration of Helsinki Principles. Diagnosis of vitiligo
was based on clinical examination done by dermatologists.
Clinically, the cases were classified as having generalized (vulgaris,
acrofacial, and universalis) or localized (focal, acral, mucosal, and
segmental) forms of vitiligo. The replication study was carried out on
355 vitiligo cases from Gujarat, a state in west of India (Table 1).
It may be pertinent to mention here that the two groups studied in
the initial and replication studies form two independent endogamous
groups that do not inter-marry.
Unaffected controls
A total of 902 ethnically matched unaffected controls from North
India were used in the initial study and 441 ethnically matched
unaffected controls from Gujarat were studied in the replication
study. None of the unaffected controls had personal or family history
of vitiligo or any other autoimmune disease. Of the 902 controls
from North India, blood samples of 308 were collected at National
Institute of Immunology, Dr Ram Manohar Lohia Hospital and All
India Institute of Medical Sciences, New Delhi, and the remaining
594 samples were procured from the Institute of Genomics and
Integrative Biology, New Delhi, which were collected from the
aforesaid states of North India as a part of the Indian Genome
Variation program, and the details of the sample collection have
been explained elsewhere (Consortium, 2005).
Study of HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles
DNA extraction was carried out by standard procedures from blood
samples collected in anticoagulant EDTA. Alleles of HLA-A, HLA-B,
HLA-C, and HLA-DRB1 were studied using PCR, followed
by hybridization with sequence-specific oligonucleotide probes as
described earlier (Israni et al., 2009), using a bead-based technology
(Luminex, Austin, TX) following the manufacturer’s instructions
(Labtype SSO kit from One Lambda, Canoga Park, LA). All North
Indian samples were typed for HLA-A, HLA-B, and HLA-DRB1 loci.
A total of 404 vitiligo and 438 unaffected control samples from
North India were typed for HLA-C locus. Of the 355 Gujarat cases,
354, 353, and 355 cases were typed for HLA-A, HLA-B, and HLA-
DRB1 loci, respectively, and of the 441 unaffected controls from
Gujarat population, 408, 407, and 441 individuals were typed
for three loci, respectively. Differences in the sample numbers
studied for different loci are because of amplification failures in
some samples. The latest nomenclature for the HLA system was
used to designate the alleles of the three loci studied (Marsh et al.,
2010).
132 Journal of Investigative Dermatology (2012), Volume 132
A Singh et al.
Functional Role of MHC Alleles in Vitiligo
Haplotype analysis
Estimation of HLA haplotype frequencies was carried out using the
expectation maximization algorithm (Excoffier and Slatkin, 1995;
Excoffier et al., 2005). Arlequin Ver 3.5 (Excoffier et al., 2005) was
run using the following settings: expectation maximization algorithm
performed at the haplotype level, e¼ 1e7, five significant digits for
output, 50 starting points for expectation maximization algorithm,
and a maximum of 1,000 iterations (Bettencourt et al., 2008) at
http://cmpg.unibe.ch/software/arlequin35/. Three- and four-locus
haplotypes were thus constructed for both patient and controls
samples to identify predisposing and protective haplotypes in
the two populations. Two-locus haplotypes were derived from
three-locus haplotypes.
Statistical analysis
Vitiligo samples were compared with their respective unaffected
controls using w2-analysis using Stata 9.2 statistical program. Fisher’s
exact test was used when the numbers were five or less in any group;
i.e., in cases or controls for any allele. In such cases, ORs were
calculated using Woolf’s method (Woolf, 1955) with Haldane (1956)
modification as described earlier (Rani et al., 1998).
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